학술논문
The impact of obesity on doravirine exposure in people with HIV
Document Type
Academic Journal
Author
Source
AIDS. Feb 01, 2024 38(2):267-269
Subject
Language
English
ISSN
0269-9370
Abstract
Obesity incidence is increasing among people with HIV. Doravirine is a recommended first-line antiretroviral drug in many countries with no data from people with obesity. This study investigates the exposure of doravirine 100 mg standard dose in obese versus normal weight patients using clinical data combined with physiologically based pharmacokinetic modelling. Results from both approaches showed an elevated doravirine exposure during obesity, yet within the safety range of doravirine with no need for dose modification.